Actovegin vs ARA-290

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

Actovegin and ARA-290 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares Actovegin and ARA-290 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

ActoveginARA-290
CategoryPain ManagementPain Management
Regulatory status (US)Research use onlyResearch use only
Typical dosage5-10 ml2-4 mg
Frequencymultiple weeklydaily for cycles
Reported benefitsCirculation-related pain relief, tissue oxygenation, healing supportNeuropathic pain reduction, nerve protection, diabetic neuropathy support
Reported side effectsRare allergic reactionsGenerally well-tolerated

Key differences

Primary use. Actovegin is categorised under Pain Management, while ARA-290 falls under Pain Management. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. Actovegin: not FDA-approved; treated as a research compound. ARA-290: not FDA-approved; treated as a research compound.

Dosing. Actovegin is typically dosed at 5-10 ml (multiple weekly). ARA-290 is typically dosed at 2-4 mg (daily for cycles).

Can you stack them?

Some protocols combine peptides, but stacking Actovegin and ARA-290 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between Actovegin and ARA-290?
Actovegin and ARA-290 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status. Actovegin is not FDA-approved; generally classified as a research compound, whereas ARA-290 is not FDA-approved; generally classified as a research compound.
What is Actovegin used for?
Hypoxic pain and healing.
What is ARA-290 used for?
Neuropathic pain specialist.
Can you take Actovegin and ARA-290 together?
Some users combine peptides within a single protocol, but stacking Actovegin and ARA-290 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is Actovegin or ARA-290 FDA-approved?
Actovegin is not FDA-approved; generally classified as a research compound. ARA-290 is not FDA-approved; generally classified as a research compound.

Read the full articles

  • Actovegin — full monograph: mechanism, research, dosing & references
  • ARA-290 — full monograph: mechanism, research, dosing & references

More Pain Management comparisons

← All peptide comparisons